1989 Fiscal Year Final Research Report Summary
A basic study on a novel combination chemotherapy for oral cancer.
| Project/Area Number |
63570932
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
外科・放射線系歯学
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
KUSAMA Mikio Tokyo Med. Dent. Univ., Faculty of Dentistry, instructor, 歯学部第二口腔外科, 助手 (60124690)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ONO Tiaki Tokyo Med. Dent. Univ., Faculty of Dentistry, lecturer, 歯学部第二口腔外科, 講師 (80014207)
|
|---|
| Project Period (FY) |
1988 – 1989
|
| Keywords | MTX / 5-FU / combination chemotherapy / chemotherapy / oral cancer / colony forming assay / chemosensitivity test / carcinoma cell line |
|---|
| Research Abstract |
(1) Chemosensitivity test was performed by colony forming assay using four oral squamous cell carcinoma cell lines, in order to examine the usefulness of combination chemotherapy of MTX and 5-FU. As a result, (1) at the concentration of the drugs that are clinically used, MTX (2.5 mg/l) had less effect than 5-FU (16 mg/l).(2) These two drug's effect was dose-dependent and time- dependent manner. (3) In combination of MTX and 5-FU, the number of colony was decreased effectively in three of these cell lines, although in one of these cell lines these drug combination had less effect than 5-FU only. However we clinically obtained good results in combination chemotherapy of MTX.5-FU. These results seemed to indicate that tumor cell in vitro may not react as a cell in vivo to these drugs, and that influx and exflux of these drugs in a cell in vitro may be different from those in vivo. However, we demonstrated in this study that the combination chemotherapy of MTX. 5-FU seemed to be available in some squamous cell carcinoma.
(2) We tried to use low dose MTX-5-FU sequential combination chemotherapy (MF therapy) for previously untreated oral cancer preoperatively. The overall response rate was 76.9%. The down-staging rate was 63.3%. In 40% of these patients, active cancer tissue has disappeared in histopathologic findings. Five year survival rate was 75%. We conclude that this initial chemotherapy prior to operation is highly effective in the treatment of this group of advanced stage.
|
